Health Catalyst Earnings Call Maps Costly Transition

Health Catalyst ((HCAT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Health Catalyst’s latest earnings call struck a cautiously optimistic tone as management highlighted a clean revenue and EBITDA beat alongside solid cash generation and tighter cost controls. Executives were equally direct about migration-related churn, temporary margin pressure and restructuring risks, framing 2026 as a heavy transition year designed to strengthen the company’s long‑term earnings power.

Revenue Beat and Shift Toward Technology

Health Catalyst delivered Q1 2026 revenue of $70.8 million, topping the high end of its $68 million to $70 million guidance range and signaling resilient demand amid change. Technology revenue reached $49.5 million versus $21.3 million from professional services, underscoring a deliberate pivot toward higher‑margin software and data products.

EBITDA Outperformance and Margin Gains

Adjusted EBITDA came in at $9.1 million, above the $7 million to $8 million outlook and up sharply from $6.3 million a year earlier, reflecting better operating leverage. Adjusted gross margin improved to 51.5% from 49.2%, a 2.3‑point expansion that came despite known cost headwinds tied to platform migrations.

Tighter Operating Expenses Support Profitability

Adjusted operating expenses fell to $27.3 million, or 39% of revenue, down from $32.8 million, or 41%, in the prior‑year quarter, a roughly 17% dollar reduction. Management expects quarterly adjusted operating expenses to decline a further $3 million to $4 million versus Q1 as its restructuring program takes hold.

Cash Balance Strengthens During Transition

The company ended the quarter with about $108.8 million in cash, cash equivalents and short‑term investments, up $13.1 million since year‑end 2025, reinforcing balance‑sheet flexibility. This growing cash cushion gives Health Catalyst room to absorb restructuring costs and migration impacts while continuing to invest in its technology platform.

Project NEXUS Targets $30 Million in Savings

Management unveiled Project NEXUS, a structural cost program aimed at roughly $30 million in annualized run‑rate savings, blending direct and indirect efficiencies. About $22 million will come from a 9% headcount reduction and non‑personnel cuts, with the remaining $8 million from indirect savings, and most restructuring charges are expected in Q2.

Product and AI Momentum Boost Productivity

The company emphasized its AI roadmap built on 18 years of proprietary healthcare improvement data, citing encouraging customer feedback on its Ignite Intelligence cost‑management tool. An engineering pilot that combines small “pods” with AI agents has doubled story points per developer in early tests, hinting at meaningful long‑term productivity gains.

Guidance Reinstated and New Bookings Metric

Health Catalyst reinstated full‑year 2026 guidance, targeting $260 million to $265 million in revenue and $30 million to $33 million in adjusted EBITDA, signaling confidence in its plan. Management also introduced a total bookings metric, expecting $22 million to $26 million in new 2026 bookings that typically turn into revenue within three to six months.

Migration‑Driven Churn Clouds Near‑Term Growth

The accelerated move from its DAS platform to Ignite has created churn pressure, with management now estimating about $30 million of annualized recurring revenue still at risk. They expect this to translate into roughly a $20 million revenue headwind in 2026 and about $10 million in 2027 even after assuming retention of at least $22 million of previously flagged accounts.

Deliberate Decline in Professional Services

Professional services revenue fell to $21.3 million and is expected to keep shrinking as the company intentionally emphasizes scalable technology contracts over services work. Management projects services revenue exiting 2026 in the $55 million to $65 million annual range, implying a smaller but more strategically aligned services base.

Low Services Margins and Transitional Pressure

Adjusted professional services gross margin was just 19.4% in Q1 and is expected to decline into the mid‑ to low‑teens for the full year as migrations continue. While painful near term, management views these weaker services margins as temporary and tied to helping clients move to the new platform and reset the revenue mix.

Duplicate Hosting and Data Loading Weigh on Tech Margins

Adjusted technology gross margin was 55.3% and was dragged down by duplicate hosting costs as customers are migrated to Ignite and by heavy data‑loading costs for health information exchanges. These transitional burdens are expected to cap near‑term expansion, though management still targets technology margins exiting 2026 in the mid‑60% range.

Restructuring Charges and Execution Risk

Project NEXUS brings near‑term financial friction, with about $4 million of restructuring charges anticipated in Q2 and only a gradual ramp in savings thereafter. Management acknowledged execution risk in delivering the full $30 million run‑rate benefit and in the timing, as not all efficiencies will be realized within 2026.

Revenue Pressure and Timing Uncertainty

Executives were frank that migration and simplification efforts will keep revenue under pressure, with most of the hit expected in 2026 but some extending into 2027. This creates uncertainty around short‑term growth trajectories even as the company argues the transition will lead to more durable, higher‑margin revenue over time.

Forward‑Looking Guidance and Transition Outlook

Looking ahead, Health Catalyst sees Q2 2026 revenue of $68 million to $70 million and adjusted EBITDA of $9 million to $10 million, implying stable profitability despite restructuring charges. For the full year, guidance includes falling adjusted operating expenses, a modest reduction in cost of revenue and exiting technology margins in the mid‑60s, even as migration‑related headwinds and services mix shifts weigh on top‑line growth.

Health Catalyst’s earnings call painted a picture of a company trading near‑term comfort for long‑term efficiency and scalability, combining cost cuts with focused AI‑driven product investment. Investors will be watching closely to see if management can execute on Project NEXUS, manage churn from migrations and lift technology margins as promised while sustaining its recent profitability gains.